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To positively modulate multiple myeloma (MM) bone disease,
understanding the mechanism of bone destruction is required to
provide better targeted therapy. Specific molecular genetic lesions
and tumor cell–stroma interactions influence the clinical course and
response to therapy, all of which can vary markedly.1,2 Our recent
study demonstrates that an increased chromosomal instability (CIN)
signature is associated with drug resistance and poor prognosis.3,4
High expression of NEK2, one of the CIN genes, has been shown to
induce premature splitting of centrosomes, while suppression of
NEK2 blocks spindle and chromosome segregation, resulting in
accumulation of multiple centrosomes.5,6 Interestingly, we found
that NEK2 expression is highly correlated with the expression of
Heparanase 1 (HPSE), and its expression is significantly increased in
the few myeloma cells still present in complete remission and not
unexpectedly also in relapse.3 Although the tumor cell number is
markedly decreased in remission patients, bone osteolysis still
continues, suggesting that drug-resistant MM cells with high
expression of NEK2 and HPSE, may play a critical role in bone
destruction or prevent the repair of bone disease during remission.
In this study, we investigated whether MM patients with high
expression of NEK2 in MM cells show increased focal bony lesions.
NEK2 expression was examined in CD138+ MM cells using
Affymetrix U133Plus2 microarray (Affymetrix, Santa Clara, CA,
USA) and correlated with bone focal lesions determined by either
fluorine-18 fluorodeoxyglucose positron emission tomography
(FDG-PET) scan or magnetic resonance imaging (MRI) in 244 newly
diagnosed MM patients enrolled in the total therapy 2 (TT2)
clinical trial.7,8 We found that NEK2 levels were positively
correlated with focal lesions as assessed by both FDG-PET and
MRI. On FDG-PET test, 89 cases showed no detectable bone lytic
lesion and 155 cases had one or more lesions.9,10 NEK2 levels were
higher in purified MM cells from patients who had one or more
lesions compared to patients with no lytic lesions on FDG-PET (the
median signals of probe set 211080_s_at were 114.8 and 198.2,
respectively, P= 7.24 × 10− 10) (Figure 1a). NEK2 expression was
also compared between MM patients with or without bone lytic
lesions defined by MRI. As shown in Figure 1b, NEK2 signals in
patients with one or more focal bone lesions (n= 170) were
Figure 1. High expression of NEK2 in MM cells is positively correlated with bone lytic lesions in newly diagnosed MM patients. (a) Bar-view represents
the correlation of NEK2 gene expression in MM cells from 89 patients without bone lytic lesion and 155 patients with one or more bone lesions on
FDG-PET scan. (b) Bar-view represents the correlation of NEK2 gene expression in MM cells from 74 patients without bone lytic lesion and 174
patients with one or more bone lesions on MRI. (c) Box-plots show the expression of NEK2 and HPSE in 50 samples with high-NEK2 and low-NEK2.
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significantly higher compared to patients without bone lytic
lesions (n= 74; the median signals were 189.8 and 115.6,
respectively, P= 2.96 × 10− 8). These data suggest that high NEK2
expression in MM cells correlates indeed with focal bone lesions in
MM patients.
In order to determine the factor related to NEK2 and causing bone
damage in MM disease, we examined genes highly correlated with
NEK2 expression in MM cells which had been published by our
group previously.3 HPSE was one of the 70 genes highly positively
correlated with NEK2 expression in MM cells. HPSE is an
enzymatically active endoglycosidase that degrades heparan sulfate
at specific intra-chain sites.11 Expression of HPSE is relatively low or
undetectable in normal tissues but it is upregulated in many human
tumors, including MM. It was recently demonstrated that heparanase
promotes chemoresistance in MM.12 High expression of HPSE has
also been linked to local and systemic osteolysis in MM.13 We
compared HPSE expression in primary MM cells between 50 high-
NEK2 and 50 low-NEK2 samples, HPSE is highly positively correlated
with NEK2 expression (Figure 1c). Analysis of GEPs in ARP1 MM cells,
which either overexpressed NEK2 (NEK2 OE) or with silenced NEK2
(NEK2 shRNA) revealed that HPSE was highly correlated with NEK2
expression. GEP data showed that HPSE was increased 2.5 fold in
NEK2 OE MM cells, and decreased 3.3-fold in NEK2-shRNA ARP1 cells
compared to the control.3 We then verified this positive correlation
between NEK2 and HPSE expression using both quantitative
reverese transcription PCR and western blotting. HPSE expression
was significantly upregulated in ARP1 and OCI-MY5 NEK2 OE MM
cells at both the mRNA and protein levels (Supplementary Figures
S1a and b) when compared to ARP1 and OCI-MY5 cells infected with
empty vector (EV), while it was markedly downregulated in ARP1
and OCI-MY5 cells with silenced NEK2 (Supplementary Figures S1c
and d). Since HPSE is a secreted enzyme, we also examined HPSE
secretion in conditioned media (CM) by ELISA in NEK2 OE and EV
ARP1 and OCI-MY5 MM cell lines; soluble HPSE levels were
significantly increased in NEK2 OE MM cells compared to control
MM cells (Supplementary Figure S1e; Po0.05).
To determine whether high NEK2 promotes osteoclast (OCL)
differentiation, bone marrow macrophages (BMMs) derived from
primary MM samples were co-cultured for up to 14 days with 50%
conditioned media (CM) from NEK2 OE and control (EV) MM cell
lines, ARP1 and OCI-MY5. Details are in Supplementary Methods.
Tartrate-resistant acid phosphatase (TRAP) staining was performed
to evaluate full OCL differentiation. TRAP+ OCLs were not detected
in BMMs only incubated with regular media (data no shown). The
number of TRAP+ OCL was significantly increased after co-culturing
with NEK2 OE CM compared to EV CM (Figure 2a; Po0.05).
Consistently, the number of TRAP+ OCL was significantly decreased
after co-culturing with NEK2 shRNA CM (Figure 2a; Po0.05) when
compared to EV CM. Osteoclast quantification was determined in
each sample (Supplementary Figure S2a). We subsequently
examined whether HPSE was involved in NEK2-induced osteoclas-
togenesis in NEK2 OE MM cells. A doxycycline-inducible HPSE
shRNA (NEK2 OE-shHPSE) or scrambled control was transfected into
NEK2 OE ARP1 and OCI-MY5 MM cells to determine whether
knockdown of HPSE decreases NEK2-induced OCL differentiation.
As shown in the Figure 2b and Supplementary Figure S2b, the
number of TRAP+ OCLs was significantly decreased from 4.4 ±1.7
and 5.3± 2.5 per area to 1.9 ± 1.1 in ARP1 and 1.4± 1.1 in OCI-MY5
cell lines, respectively (Supplementary Figure S2b; Po0.05). We also
tested the HPSE inhibitor, Roneparstat (formerly known as SST0001),
in the culture media for 48 h, OCL differentiation was significantly
inhibited in NEK2 OE CM (data not shown). Consistently, OCL
differentiation markers, such RANK, TRAP, NFATc1 and CTSK, were
upregulated in BMMs cultured with NEK2 OE CM but this
upregulation was abrogated by Roneparstat (OE SST) in both CMs
collected from OCI-MY5 and ARP1 NEK2 OE cells (data not shown).
These results support the conclusion that NEK2 induces OCL
differentiation via upregulation and secretion of HPSE by MM cells.
We also confirmed that NEK2 is a driver of osteolysis in MM
in vivo. ARP1 cells transfected with luciferase and NEK2 OE or EV
were injected into NOD.Cγ-Rag1 mice via the tail vein (n=6 for
NEK2 OE and n=3 for EV group). Details are in Supplementary
Methods. One week after injection of MM cells, 3 of 6 NEK2 OE mice
were treated with saline solution or HPSE inhibitor, Roneparstat
(60 mg/kg, intraperitoneal injection/twice a day) for 3 weeks. All
mice were killed when hind limb paralysis occurred in the control
Figure 2. Overexpression of NEK2 in MM cells enhances osteoclast differentiation and bone destruction. (a) Human bone marrow
macrophages (BMMs) from MM patients were cultured in the conditioned media collected from the control (EV), NEK2 OE and NEK2 shRNA
ARP1 and OCI-MY5 lines for 14 days. Osteoclasts were detected by TRAP staining. (b) BMMs were cultured in the conditioned media collected
from the control (EV), NEK2 OE, and NEK2 OE-shRNA HPSE (NEK2 OE shHPSE) ARP1 and OCI-MY5 lines for 14 days. Osteoclasts were detected
by TRAP staining. (c) Representative X-ray, μCT and histological images for H&E and TRAP staining of bones from mice treated with ARP1 EV,
ARP1 NEK2 OE and NEK2 OE plus Roneparstat (NEK2 OE SST). Red arrows indicate bone lytic lesions by X-ray.
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group mice. Human kappa light chain secretion was analyzed as an
indirect indicator of tumor burden (data not shown). The femur and
tibia bones from one mouse leg were fixed with 10% neutral
buffered formalin for 7 days for the analyses by X-ray and microCT.
The femur and tibia bones from another leg were decalcified for
2 weeks for histological staining. X-ray radiology analysis revealed
bone lytic lesions in the hind limb of mice injected with NEK2 OE
cells (Figure 2c). MicroCT showed that bone volume and thickness
of trabecular bone were decreased significantly in mice injected
with NEK2 OE ARP1 cells compared to EV ARP1 cells. Strikingly,
treatment with the HPSE inhibitor Roneparstat (NEK OE SST)
markedly reduced bone mass loss for both trabecular bone and
cortical bone thickness induced by NEK2 overexpression
(Supplementary Figure S2c). TRAP staining of decalcified bone
sections revealed a significant increase in the number of OCLs in
the trabecular bone area in mice injected with NEK2 OE cells
compared to EV mice, while addition of the Roneparstat reduced
the number of OCLs (Supplementary Figure S2d).
The scope of this work was to determine the functional role of
NEK2 in mediating bone destruction in MM and to apply this
knowledge to develop novel therapies. In this study, we demon-
strate that NEK2 plays an important role in MM bone disease. We
evaluated the role of NEK2 in bone destruction of MM via clinical
gene expression profiling data analysis and in vitro and in vivo
mouse models. Further, treatment with the heparanase inhibitor
Roneparstat, a Phase 1 drug in MM treatment,14 markedly inhibited
OCL differentiation and rescued bone mass loss induced by NEK2
overexpression, suggesting that targeting NEK2 and/or its signaling
pathway may be not only for prevent MM disease relapse but also
bone destruction. Future study will explore the molecular mechan-
ism(s) by which NEK2 upregulates and activates HPSE in MM cells
resulting in bone damage in MM patients and determine whether
NEK2 signaling is involved in osteoblast differentiation.
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